Morrow Thomas
Manag Care. 2018 Jun;27(6):31-33.
Trogarzo (ibalizumab-uiyk) is a CD4-directed post-attachment HIV-1 inhibitor, indicated for use with other antiretroviral inhibitors in adults with multidrug resistant HIV-1 infection who aren't responding to their antiretroviral regimen. It is considered an advance. But FDA approval was based on a study of only 40 people-and it had no control group.
特罗加佐（ibalizumab-uiyk）是一种靶向CD4的HIV-1附着后抑制剂，适用于与其他抗逆转录病毒抑制剂联合使用，用于治疗对其抗逆转录病毒治疗方案无反应的多重耐药HIV-1感染的成人患者。它被认为是一项进展。但美国食品药品监督管理局（FDA）的批准仅基于一项仅40人的研究，而且该研究没有对照组。
